Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,801–1,900 of 4,628
Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
Albera, C., Verri, G., Sciarrone, F., Sitia, E., Mangiapia, M., & Solidoro, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091237 · Cited by 17
Cottin, V., Spagnolo, P., Bonniaud, P., Nolin, M., Dalon, F., Kirchgässler, K.-U., Kamath, T. V., Ganse, E. H. V., & Belhassen, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.802989 · Cited by 22
“Pirfenidone and nintedanib, currently the only approved antifibrotic therapies for IPF (3), slow lung function decline and reduce the risk of respiratory-related hospitalizations, which are associated with high morbidity and mortality (4, 5).”
BackgroundSelf-citationKomatsu, M., Yamamoto, H., Ichiyama, T., Kawakami, S., Uehara, T., Yoshikawa, Y., Kitaguchi, Y., Ushiki, A., Yasuo, M., & Hanaoka, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262795 · Cited by 18
“1) years in the INPULSIS trials [11], 71 (SD: 8) years in the USA [19], and 71.”
BackgroundResultInfluentialInterstitial lung disease progression after genomic usual interstitial pneumonia testing
Chaudhary, S., Weigt, S. S., Neto, M. L. R., Benn, B. S., Pugashetti, J. V., Keith, R. C., Chand, A., Oh, S., Kheir, F. M., Ramalingam, V. S., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01245-2022 · Cited by 22
Ruaro, B., Gandin, I., Pozzan, R., Tavano, S., Bozzi, C., Hughes, M., Kodric, M., Cifaldi, R., Lerda, S., Confalonieri, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020307 · Cited by 19
“The efficacy of nintedanib′s antifibrotic properties first emerged in the phase II TOMORROW study [14] and was later confirmed by the phase III IMPULSIS-1 and IMPULSIS-2 studies [15].”
BackgroundPaulín, F., Babini, A. M., Mamani, M. N., Mercado, J. F., & Caro, F. M. (2017) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.17002162 · Cited by 22
Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation
Gu, Y., Huang, B., Yang, Y., Qi, M., Lu, G., Xia, D., & Li, H. (2018) · Inflammation · doi:10.1007/s10753-018-0745-3 · Cited by 17
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
Baughman, R. P., & James, W. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54429-0.00020-3 · Cited by 17
Han, S., Lee, J. E., Kang, S., So, M., Jin, H. K., Lee, J. H., Baek, S., Jun, H., Kim, T. Y., & Lee, Y. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae035 · Cited by 19
The future of clinical trials in idiopathic pulmonary fibrosis
Spagnolo, P., & Maher, T. M. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001099 · Cited by 20
Mooney, J. J., Jacobs, S. S., Lefebvre, E. A., Cosgrove, G. P., Clark, A., Turner, S., Decaris, M. L., Barnes, C. N., Jurek, M., Williams, B., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202409-969oc · Cited by 20
Vascular involvement in idiopathic pulmonary fibrosis
Mondoni, M., Rinaldo, R. F., Ryerson, C. J., Albrici, C., Baccelli, A., Tirelli, C., Marchetti, F., Cefalo, J., Nalesso, G., Ferranti, G., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00550-2024 · Cited by 22
Walters, T. M., Leong, M. C. H., Montesi, S. B., Ryerson, C. J., & Khor, Y. H. (2025) · European Respiratory Review · doi:10.1183/16000617.0238-2024 · Cited by 20
Alonso-González, A., Jáspez, D., Lorenzo-Salazar, J. M., Ma, S., Strickland, E., Mychaleckyj, J. C., Kim, J. S., Huang, Y., Adegunsoye, A., Oldham, J. M., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00045-1 · Cited by 24
Imai, R., Bermea, R. S., Zhao, S. H., Montesi, S. B., Singh, A., Flashner, B. M., Synn, A. J., Munchel, J. K., Rice, M. B., Soskis, A., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.05.036 · Cited by 20
Brazee, P. L., Allen, N., Knipe, R. S., Redente, E. F., & Saux, C. J. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2649-9402 · Cited by 27
Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis
Hirasawa, Y., Abe, M., Terada, J., Sakayori, M., Suzuki, K., Yoshioka, K., Kawasaki, T., Tsushima, K., & Tatsumi, K. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101917 · Cited by 16
Erre, G. L., Sebastiani, M., Manfredi, A., Gerratana, E., Atzeni, F., Passiu, G., & Mangoni, A. A. (2021) · Drugs in Context · doi:10.7573/dic.2020-8-6 · Cited by 20
Nishino, K., Yoshimatsu, Y., Muramatsu, T., Sekimoto, Y., Mitani, K., Kobayashi, E., Okamoto, S., Ebana, H., Okada, Y., Kurihara, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88064-3 · Cited by 19
Aronson, K. I., & Suzuki, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.745908 · Cited by 21
Wu, S., Tsai, J., Pan, H., Arbiser, J. L., Elia, L., & Sheu, M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15806 · Cited by 22
Early Detection and Staging of Lung Fibrosis Enabled by Collagen-Targeted MRI Protein Contrast Agent
Ibhagui, O. Y., Li, D., Han, H., Peng, G., Meister, M. L., Gui, Z., Qiao, J., Salarian, M., Dong, B., Yuan, Y., et al. (2023) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.3c00023 · Cited by 19
Richter, P., Cardoneanu, A., Dima, N., Bratoiu, I., Rezuș, C., Burlui, A., Costin, D., Macovei, L. A., & Rezuş, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119388 · Cited by 27
“Nintedanib is a tyrosine kinases inhibitor previously approved for idiopathic pulmonary fibrosis following INPULSIS studies [77].”
BackgroundIdiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
Tu, H., Han, L. W., Hsu, J. C., Kamath, N., & Pan, L. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231181537 · Cited by 17
Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis
Zhao, J. L., Fares, J., George, G., Maheu, A. R., Loizidis, G., Roman, J., Kramer, D., Li, M., & Summer, R. S. (2023) · Respirology · doi:10.1111/resp.14563 · Cited by 19
Shu, Y., Xue, S., Wang, T., Gao, R., Zeng, H., Wang, Q., & Jia, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1086214 · Cited by 20
“We also reviewed two 52-week randomized, double-blind, replicated phase III trials of nintedanib in patients with IPF Frontiers in Oncology 07 (INPULSI-1 and INPULSI-2) (61).”
BackgroundInfluentialThe Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
Vats, A., & Chaturvedi, P. (2023) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s419474 · Cited by 28
Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary Fibrosis
Kim, J. S., Ma, S., Ma, J. Z., Huang, Y., Bonham, C. A., Oldham, J. M., Adegunsoye, A., Strek, M. E., Flaherty, K. R., Strickland, E., et al. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.09.035 · Cited by 19
Self-citationLeuschner, G., Semenova, A., Mayr, C. H., Kapellos, T. S., Ansari, M., Seeliger, B., Frankenberger, M., Kneidinger, N., Hatz, R. A., Hilgendorff, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108345 · Cited by 18
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis
Simonetti, J., Ficili, M., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2305126 · Cited by 18
Self-citationXu, R., Zhan, M., Peng, L., Pang, X., Yang, J. H., Zhang, T., Jiang, H., Zhao, L., & Chen, Y. (2015) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3299 · Cited by 17
Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Covvey, J. R., & Mancl, E. E. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014551015 · Cited by 20
Cough in interstitial lung disease
Garner, J. L., George, P. M., & Renzoni, E. A. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.10.009 · Cited by 19
Lee, J. S., & Fischer, A. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1139454 · Cited by 18
Nintedanib for treating idiopathic pulmonary fibrosis
Hayton, C., & Chaudhuri, N. (2016) · British Journal of Healthcare Management · doi:10.12968/bjhc.2016.22.5.250 · Cited by 17
Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis
Geng, X., Dufu, K., Hutchaleelaha, A., Xu, Q. R., Li, Z., Li, C.-M., Patel, M. P., Vlahakis, N. E., Lehrer‐Graiwer, J., & Oksenberg, D. (2016) · Physiological Reports · doi:10.14814/phy2.12965 · Cited by 20
Antioxidants in respiratory diseases: Basic science research and therapeutic alternatives
Alvarado, A., & Arce, I. (2016) · Clinical Research and Trials · doi:10.15761/crt.1000163 · Cited by 22
Spagnolo, P. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_11 · Cited by 18
New treatment directions for IPF: current status of ongoing and upcoming clinical trials
Macagno, F., Varone, F., Leone, P. M., Mari, P., Panico, L., Berardini, L., & Richeldi, L. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335601 · Cited by 19
Self-citationRecipient selection process and listing for lung transplantation
Verleden, G. M., Dupont, L., Yserbyt, J., Schaevers, V., Raemdonck, D. E. V., Neyrinck, A., & Vos, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.90 · Cited by 19
Diagnosis of Idiopathic Pulmonary Fibrosis “Pragmatic Challenges in Clinical Practice”
Tzilas, V., Τzouvelekis, Α., Chrysikos, S., Papiris, S. A., & Bouros, D. E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00151 · Cited by 21
Petroulia, V., Funke, M., Zumstein, P., et al. (2017) · Investigative Radiology · doi:10.1097/rli.0000000000000405 · Cited by 17
High burden of Aspergillus fumigatus infection among chronic respiratory diseases
Fukuda, Y., Homma, T., Suzuki, S., Takuma, T., Tanaka, A., Yokoe, T., Ohnishi, T., Niki, Y., & Sagara, H. (2018) · Chronic Respiratory Disease · doi:10.1177/1479972318761654 · Cited by 21
Imaging biomarkers and staging in IPF
Walsh, S. L. F. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000507 · Cited by 19
The immunomodulatory role of interleukin-35 in fibrotic diseases
Luo, M., Peng, H., Chen, P., & Zhou, Y. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1564041 · Cited by 19
“On these basis, two drugs Pirfenidone [19] and Nintedanib [20] have been recently approved by US FDA for treatment of”
BackgroundInfluentialPirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study
Bennett, D., Refini, R. M., Valentini, M. L., Fui, A., Fossi, A., Pieroni, M., Mazzei, M. A., & Rottoli, P. (2019) · Lung · doi:10.1007/s00408-019-00203-w · Cited by 17
Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice
Susutlertpanya, W., Wakuda, H., Otani, N., Kuramoto, T., Li, L., Kuranari, M., Sekiguchi, A., Kudo, H., Uchida, T., Imai, H., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.014 · Cited by 20
Clay, E., Cristeau, O., Chafaie, R., Pinta, A., Mazaleyrat, B., & Cottin, V. (2019) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2019.1626171 · Cited by 17
“tor, and fibroblast growth factor receptor [11,12].”
Self-citationHarari, S. A., Cereda, F., Pane, F., et al. (2019) · Medicina · doi:10.3390/medicina55090606 · Cited by 17
“The guidelines indicate surgical lung biopsy (SLB) for those patients suspected of having IPF who are however at minimal surgical risk.”
BackgroundInfluentialJudson, M. A. (2019) · F1000Research · doi:10.12688/f1000research.20696.1 · Cited by 19
Pathology of Idiopathic Interstitial Pneumonias
Zaizen, Y., & Fukuoka, J. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.11.006 · Cited by 17
Respiratory surveillance in mineral dust-exposed workers
Wood, C. J., & Yates, D. H. (2020) · Breathe · doi:10.1183/20734735.0362-2019 · Cited by 17
“There are many potentially effective treatments for coal mine lung dust-related disorders that have yet to be evaluated, including antifibrotic therapies that have been shown to be effective in trials into lung fibrosis from other causes [46, 47].”
BackgroundIdentification of a unique temporal signature in blood and BAL associated with IPF progression
Norman, K. C., O’Dwyer, D. N., Salisbury, M. L., DiLillo, K. M., Lama, V. N., Xia, M., Gurczynski, S. J., White, E. S., Flaherty, K. R., Martínez, F. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67956-w · Cited by 17
Self-citationWang, Y., Miao, L., Hu, Y., & Zhou, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01636 · Cited by 17
“Two phase III trials (42) evaluated the benefit of nintedanib in idiopathic pulmonary fibrosis (IPF) patients; the proportion of patients with AE-IPF within 1 year was 3.”
BackgroundSekine, A., Wasamoto, S., Hagiwara, E., Yamakawa, H., Ikeda, S., Okabayashi, H., Oda, T., Okuda, R., Kitamura, H., Baba, T., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.10.002 · Cited by 19
Kai, Y., Matsuda, M., Fukuoka, A., Hontsu, S., Yamauchi, M., Yoshikawa, M., & Muro, S. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13935 · Cited by 16
“Nintedanib, a tyrosine kinase inhibitor targeting fibroblast growth factor receptor, vascular endothelial growth factor (VEGF), and platelet-derived growth factor receptor,(3) has been reported to slow down the decline of lung function and incidences of acute exacerbation.(3) However, the effects of nintedanib on lung…”
BackgroundAntifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
Bos, S., Sadeleer, L. D., Vanstapel, A., Beeckmans, H., Sacreas, A., Yserbyt, J., Wuyts, W. A., & Vos, R. (2021) · European Respiratory Review · doi:10.1183/16000617.0050-2021 · Cited by 26
Interstitial lung abnormalities – current knowledge and future directions
Axelsson, G. T., & Guðmundsson, G. (2021) · European Clinical Respiratory Journal · doi:10.1080/20018525.2021.1994178 · Cited by 16
Insights gained in the pathology of lung disease through single‐cell transcriptomics
Carraro, G., & Stripp, B. R. (2022) · The Journal of Pathology · doi:10.1002/path.5971 · Cited by 17
Ginkgolic acid improves bleomycin‐induced pulmonary fibrosis by inhibiting SMAD4 SUMOylation
Yu, L., Bian, X., Zhang, C., Wu, Z., Huang, N., Yang, J., Jin, W., Feng, Z., Li, D., Huo, X., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8002566 · Cited by 19
Caro, F. M., Buendía-Roldán, I., Noriega, L., Alberti, M. L., Amaral, A. F., Arbo, G., Auteri, S. J., Bermúdez, A., Curbelo, P., Verduzco, M. D. J. D., et al. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.04.007 · Cited by 20
Self-citationO’Flaherty, B. M., Matar, C. G., Wakeman, B. S., Garcia, A., Wilke, C. A., Courtney, C. L., Moore, B. B., & Speck, S. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135719 · Cited by 18
Abdelhameed, A. S., Ajmal, M. R., Ponnusamy, K., Subbarao, N., & Khan, R. H. (2016) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2016.02.048 · Cited by 17
Proton Pump Inhibitors in IPF: A Call for Clinical Trials
Ghebre, Y. T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00499 · Cited by 21
Gajjala, P. R., Bruck, H., Noels, H., Heinze, G., Ceccarelli, F., Kribben, A., Sáez-Rodríguez, J., Marx, N., Zidek, W., Jankowski, J., et al. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01823-8 · Cited by 15
Frye, B. C., Rump, I. C., Uhlmann, A., Schubach, F., Ihorst, G., Grimbacher, B., Zissel, G., & Quernheim, J. M. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100575 · Cited by 18
Xu, D., Zhang, Y., Dai, J., Bai, Y., Xiao, Y., & Zhou, M. (2015) · Analytical Methods · doi:10.1039/c5ay01207d · Cited by 17
Maher, T. M., Stowasser, S., Nishioka, Y., White, E. S., Cottin, V., Noth, I., Selman, M., Blahova, Z., Wachtlin, D., Diefenbach, C., et al. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000325 · Cited by 17
“Dose reductions to 100 mg two times a day and treatment interruptions are recommended to manage adverse events, based on similar recommendations as were provided in the INPULSIS trials.(30) After resolution of the adverse event, nintedanib can be reintroduced and re-escalated to 150 mg two times a day at the discretio…”
MethodSelf-citationMaximizing Deep Lung Deposition in Healthy and Fibrotic Subjects During Jet Nebulization
Samuel, J., & Smaldone, G. C. (2020) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2019.1552 · Cited by 19
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Yumura, M., Nagano, T., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173987 · Cited by 18
“Following this trial, two phase III trials (INPULSIS-1 and INPULSIS-2 trial) were conducted [59,60].”
MethodHermansky-Pudlak syndrome-2 alters mitochondrial homeostasis in the alveolar epithelium of the lung
Cuevas-Mora, K., Roque, W., Shaghaghi, H., Gochuico, B. R., Rosas, I. O., Summer, R. S., & Romero, F. (2021) · Respiratory Research · doi:10.1186/s12931-021-01640-z · Cited by 16
Sullivan, D. I., Jiang, M., Hinchie, A. M., Roth, M. G., Bahudhanapati, H., Nouraie, M., Liu, J., McDyer, J. F., Mallampalli, R. K., Zhang, Y., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.600626 · Cited by 16
“Currently, the prognosis for IPF is often worse than many cancers (5, 6), and the two drugs that exist to treat this disease have only modest effects on disease progression (7, 8).”
BackgroundSuzuki, T., Hozumi, H., Miyashita, K., Kono, M., Suzuki, Y., Karayama, M., Furuhashi, K., Hasegawa, H., Fujisawa, T., Enomoto, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88718-2 · Cited by 20
Yang, Y., dos Santos, D. M., Pantano, L., Knipe, R. S., Abe, E. A., Logue, A., Pronzati, G., Black, K. E., Spinney, J. J., Giacona, F. L., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0428oc · Cited by 20
Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside
Amratia, D., Viola, H., & Ioachimescu, O. C. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002161 · Cited by 21
Invadosome Formation by Lung Fibroblasts in Idiopathic Pulmonary Fibrosis
Lebel, M., Cliché, D. O., Charbonneau, M., Adam, D., Brochiero, E., Dubois, C. M., & Cantin, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010499 · Cited by 16
“Of n te, the capacity of IPF fibroblasts to form invadosomes was not associated with fibronectin expression (Figure S1B) or with FVC clinical measures or smoking status (Figure S2A-B).”
BackgroundInfluentialPan, L., Meng, F., Wang, W., Wang, X.-H., Shen, H., Bao, P., Kang, J., & Kong, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1072612 · Cited by 17
Kang, J., Chung, M. P., Park, M. S., Oh, I., Lee, H. B., Kim, Y. W., Park, J. S., Uh, S. T., Kim, Y. S., Jegal, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1025947 · Cited by 19
“All patients were diagnosed with IPF at the host site based on the ATS/ERS/ Japanese Respiratory Society/Latin American Thoracic Association guidelines (Raghu et al., 2011).”
BackgroundInfluentialExpert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease
Dai, H., Ma, F., Ren, Y., Chen, S.-S., & Li, Y. (2023) · Current Medical Science · doi:10.1007/s11596-022-2693-2 · Cited by 23
Palliative care for interstitial lung disease: A nationwide survey of pulmonary specialists
Fujisawa, T., Akiyama, N., Morita, T., Koyauchi, T., Matsuda, Y., Mori, M., Miyashita, M., Tachikawa, R., Tomii, K., Tomioka, H., et al. (2023) · Respirology · doi:10.1111/resp.14493 · Cited by 17
Self-citationMadsen, S. F., Sand, J. M. B., Juhl, P., Karsdal, M. A., Thudium, C. S., Siebuhr, A. S., & Bay‐Jensen, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-36416-6 · Cited by 21
Zhao, C., Yin, Y., Zhu, C., Zhu, M., Ji, T., Li, Z., & Cai, J. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102071 · Cited by 18
Takei, R., Matsuda, T., Fukihara, J., Sasano, H., Yamano, Y., Yokoyama, T., Kataoka, K., Kimura, T., Suzuki, A., Furukawa, T., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1067149 · Cited by 15
“A previous study (the INPULSIS trial) showed that patients with IPF had mean changes of about 4 points in the SGRQ total score in 52 weeks (20).”
MethodVitamin D and idiopathic pulmonary fibrosis: a two-sample mendelian randomization study
Lin, T., Zhou, F., Mao, H., Xie, Z., & Jin, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02589-z · Cited by 17
Jia, Q., Lei, Y., Chen, S., Liu, S., Wang, T., & Cheng, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02658-3 · Cited by 21
Gerokonstantis, D. T., Mantzourani, C., Gkikas, D., Wu, K., Hoang, H. N., Triandafillidi, I., Barbayianni, I., Kanellopoulou, P., Kokotos, A. C., Moutevelis‐Minakakis, P., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01422 · Cited by 16
Emerging Treatments for Childhood Interstitial Lung Disease
Bernardinello, N., Griese, M., Borie, R., & Spagnolo, P. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00603-9 · Cited by 19
Huang, X., Liang, R., Liu, Y., Yu, L., Yang, M., Shang, B., Zhang, H., Ma, J., Chen, W., & Wang, D. (2024) · Environmental Science and Pollution Research · doi:10.1007/s11356-024-33701-3 · Cited by 16
Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis
Soni, S., Antonescu, L., Ro, K., Horowitz, J. C., Mebratu, Y. A., & Nho, R. S. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.06.004 · Cited by 20
Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene
Rose, J. A., Tukpah, A.-M. C., Cutting, C. C., Wada, N., Nishino, M., Moll, M. R., Kalra, S., Choi, B., Lynch, D. A., Raby, B. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0313oc · Cited by 19
Challenges in IPF diagnosis, current management and future perspectives.
Wells, A. U., Costabel, U., Poletti, V. E., Crestani, B., Egan, J. J., Margaritopoulos, G. A., & Antoniou, K. M. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 18
Self-citationChanges in the current classification of IIP : A critical review
Neurohr, C., & Behr, J. (2015) · Respirology · doi:10.1111/resp.12553 · Cited by 21
Luzina, I. G., Lockatell, V., Todd, N. W., Kopach, P., Pentikis, H. S., & Atamas, S. P. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.224675 · Cited by 17
Beyond TGFβ – Novel ways to target airway and parenchymal fibrosis
Boorsma, C. E., Dekkers, B. G. J., van Dijk, E. M., Kumawat, K., Richardson, J., Burgess, J. K., & John, A. E. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.08.009 · Cited by 18
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Cottin, V. (2015) · Clinical Investigation · doi:10.4155/cli.15.27 · Cited by 18
Self-citationJo, H. E., Prasad, J. D., Troy, L. K., Mahar, A. M., Bleasel, J. F., Ellis, S. J., Chambers, D. C., Holland, A. E., Lake, F., Keir, G. J., et al. (2017) · The Medical Journal of Australia · doi:10.5694/mja17.00799 · Cited by 16
Ohkubo, H., Taniguchi, H., Kondoh, Y., Yagi, M., Furukawa, T., Johkoh, T., Arakawa, H., Fukuoka, J., & Niimi, A. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9508-17 · Cited by 18
Self-citationNovel management strategies for idiopathic pulmonary fibrosis
Ahmad, K., & Nathan, S. D. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1513332 · Cited by 18
Current and Future Idiopathic Pulmonary Fibrosis Therapy
Richeldi, L., Baldi, F., Pasciuto, G., Macagno, F., & Panico, L. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.006 · Cited by 18
“An increased risk of bleeding and of cardiac disorders should be evaluated in patients at higher cardiovascular and/or bleeding risk.(14) Long-term safety and efficacy of nintedanib has been assessed in the INPULSIS-ON trial, confirming the beneficial effect of nintedanib on slowing the deterioration of lung function…”
BackgroundMethodSelf-citation
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.